• MK-0812: A CCR2 Lens on the Gut–Liver Axis

  2026-08-28

  The gut–liver axis is emerging as a decisive driver of MASH biology, but epithelial barrier failure and lipid mediator signaling must ultimately be translated into hepatic inflammatory recruitment. This thought-leadership article positions MK-0812 as a research tool for testing whether CCR2-dependent monocyte trafficking links intestinal TM6SF2 deficiency to liver inflammation, while clearly separating evidence from hypothesis.

• Fast HepaRG Differentiation for HBV and HDV Studies

  2026-08-28

  Lucifora and colleagues developed a chemically accelerated HepaRG differentiation workflow that supports efficient HDV infection after only one week, while revealing a distinct limitation for HBV cccDNA formation and downstream replication. The study provides both a practical antiviral cell model and an experimental framework for separating viral entry from post-entry establishment.

• Palonosetron Hydrochloride: Evidence for CINV Prevention

  2026-08-27

  Ruhlmann and Herrstedt’s review explains why palonosetron differs pharmacologically from earlier 5-HT3 receptor antagonists, emphasizing its high receptor affinity, prolonged half-life, allosteric binding, and positive cooperativity. Its practical contribution is a critical comparison of preclinical and clinical evidence, particularly the challenge of translating receptor-level distinctions into better control of acute and delayed chemotherapy-induced nausea and vomiting.

• Selective IRAP Inhibitors from Bestatin Derivatives

  2026-08-27

  The reference study develops α-hydroxy-β-amino acid derivatives of bestatin as selective inhibitors of insulin-regulated aminopeptidase (IRAP). Combining stereoselective synthesis, biochemical profiling, cellular testing, and X-ray crystallography, the authors identify a cell-active low-nanomolar inhibitor and show that interactions with the GAMEN loop can strongly influence potency and selectivity.

• MK-0812 Workflows for CCR2 and MASH Research

  2026-08-26

  MK-0812 provides a selective way to test how CCR2-dependent monocyte movement contributes to gut–liver inflammation, from whole-blood pharmacology to tissue immune profiling. This guide translates the intestinal TM6SF2–MASH findings into practical assay designs while separating established product data from workflow starting conditions.

• Metronidazole: A Dual-Readout Assay Framework

  2026-08-26

  Metronidazole is more than a nitroimidazole antibiotic: it can support parallel studies of anaerobic antimicrobial activity and OAT3-mediated transport. This article presents a reference-grounded framework for separating transporter inhibition, antimicrobial effects, and drug-drug interaction modulation in translational assays.

• Anlotinib Inhibits Angiogenesis Through Three Kinases

  2026-08-25

  The reference study shows that anlotinib suppresses angiogenesis by inhibiting VEGFR2, PDGFRβ, and FGFR1 together with their downstream ERK signaling pathway. Its multi-factor assay design links endothelial migration, capillary-like tube formation, ex vivo vessel sprouting, and CAM neovascularization, providing a useful framework for cancer research.

• FDA-Approved Screening Identifies MERS-CoV Inhibitors

  2026-08-25

  The reference study screened 348 FDA-approved drugs in cell culture and identified chloroquine, chlorpromazine, loperamide, and lopinavir as low-micromolar inhibitors of MERS-CoV replication. Its main contribution was to show how phenotypic repurposing can rapidly generate cross-coronavirus antiviral leads, while also demonstrating that cell-based activity requires further validation before therapeutic conclusions are possible.

• SARS-CoV-2 N Condensates as an Antiviral Target

  2026-08-24

  The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a functional step in viral biology. It further shows that (-)-gallocatechin gallate disrupts N–RNA condensation and suppresses viral replication, establishing condensate control as a mechanistic antiviral strategy while highlighting important questions about specificity and translation.

• Sunitinib: Multi-Targeted RTK Inhibitor

  2026-08-24

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that blocks VEGFR, PDGFR, KIT, and RET signaling. Its research value spans tumor angiogenesis, apoptosis induction in renal cell carcinoma, cell cycle arrest at G0/G1 phase, and studies of resistance mechanisms.

• Live-Dead Cell Staining Kit for Biomaterial Testing

  2026-08-23

  Discover how the Live-Dead Cell Staining Kit can become a decision tool for evaluating biomaterial cytocompatibility, not merely a binary viability endpoint. This article connects Calcein-AM Propidium Iodide staining with mechanistic testing of multifunctional hemostatic adhesives.

• Bsa I (RNase-free): Protocol and QC Guide

  2026-08-22

  Bsa I (RNase-free) provides sequence-directed DNA cleavage for gene cloning, DNA manipulation, and other molecular biology research workflows in which RNase control is important. It is intended for scientific research only and should not be used for diagnostic, clinical, or medical applications.

• TRIB3, Ferroptosis, and Sunitinib Sensitivity in ccRCC

  2026-08-21

  A 2024 Cellular Signalling study identifies TRIB3 knockdown as a strategy for increasing clear cell renal cell carcinoma sensitivity to Sunitinib. The work links TRIB3 depletion to ferroptosis through the SLC7A11/GPX4 antioxidant axis, providing a mechanistic framework for studying resistance beyond conventional RTK signaling.

• MEDUSA Reveals Hidden Drug-Death Mechanisms

  2026-08-21

  Honeywell and colleagues introduce MEDUSA, a time-resolved modeling framework that separates drug-induced growth inhibition from cell death in pooled functional genomic screens. Applied to DNA damage responses, the method shows that p53 loss can redirect lethality from apoptosis toward a respiration-dependent nonapoptotic process, offering a stronger basis for interpreting resistance and combination strategies.

• Perospirone (SM-9018 freebase): Assay Guide

  2026-08-20

  This scenario-based guide explains how Perospirone (SM-9018 freebase), SKU BA5009, can be incorporated into viability, proliferation, receptor, and vascular ion-channel experiments. It emphasizes solvent compatibility, concentration design, controls, and interpretation of neurovascular findings without treating one assay endpoint as a complete mechanism.

7901 records 1/527 page Next 12345 下5页 Last page